Viale, G <br/><br/>
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Oct 2011 
 - 2201-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdq738  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Aromatase Inhibitors--administration & dosage<br/>Breast Neoplasms--drug therapy<br/>Chemotherapy, Adjuvant<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>ErbB Receptors--biosynthesis<br/>Female<br/>Humans<br/>Ki-67 Antigen--biosynthesis<br/>Letrozole<br/>Middle Aged<br/>Nitriles--administration & dosage<br/>Prognosis<br/>Receptors, Estrogen--biosynthesis<br/>Receptors, Progesterone--biosynthesis<br/>Tamoxifen--administration & dosage<br/>Triazoles--administration & dosage